Phase 3 results posted, week of September 28, 2026: 8 industry trials
Industry sponsors posted results for 8 Phase 3 trials on ClinicalTrials.gov in the week of September 28 to October 4, 2026. Together the trials enrolled 3,200 participants; the largest, Teva Pharmaceuticals USA's Estradiol trial, enrolled 1,050.
Compiled by code from the stream briefs and public records linked below; no model wrote this page. How we use automation
Each line below links the stream brief and the trial's ClinicalTrials.gov record, largest trial first.
The trials
- Results posted for estradiol vaginal insert study. Sponsor: Teva Pharmaceuticals USA. Condition: Dyspareunia. Interventions: Estradiol, Imvexxy. Phase: Phase 3. Enrollment: 1,050 (actual). Results first posted September 30, 2026. Record: NCT05617820.
- Results posted for SM04554 topical solution study in male androgenetic alopecia. Sponsor: Biosplice Therapeutics, Inc. Condition: Androgenetic Alopecia. Interventions: Topical SM04554 0.15% solution, Topical SM04554 0.25% solution. Phase: Phase 2/Phase 3. Enrollment: 675 (actual). Results first posted October 1, 2026. Record: NCT03742518.
- Results posted for phase 3 orforglipron study in type 2 diabetes. Sponsor: Eli Lilly and Company. Condition: Type 2 Diabetes. Intervention: Orforglipron. Phase: Phase 3. Enrollment: 546 (actual). Results first posted October 1, 2026. Record: NCT06109311 (ACHIEVE-5).
- Results posted for Atacicept study in IgA nephropathy. Sponsor: Vera Therapeutics, Inc. Conditions: IgA Nephropathy, Berger Disease. Intervention: Atacicept. Phase: Phase 3. Enrollment: 428 (actual). Results first posted October 1, 2026. Record: NCT04716231 (ORIGIN 3).
- Results posted for ABC008 study in inclusion body myositis. Sponsor: Abcuro, Inc. Condition: Inclusion Body Myositis. Intervention: ABC008. Phase: Phase 2/Phase 3. Enrollment: 272 (actual). Results first posted October 1, 2026. Record: NCT05721573.
- Results posted for LicartTM topical system study. Sponsor: IBSA Institut Biochimique SA. Condition: Soft Tissue Injuries. Intervention: Licart™ (diclofenac epolamine) topical system. Phase: Phase 3. Enrollment: 151 (actual). Results first posted September 30, 2026. Record: NCT05171673.
- Results posted for TAK-881 PK, safety study in primary immunodeficiency diseases. Sponsor: Takeda. Condition: Primary Immunodeficiency Diseases (PID). Interventions: TAK-881, HYQVIA. Phase: Phase 2/Phase 3. Enrollment: 65 (actual). Results first posted September 30, 2026. Record: NCT05755035.
- Results posted for dexmedetomidine study in dementia agitation. Sponsor: BioXcel Therapeutics Inc. Conditions: Agitation, Dementia. Intervention: BXCL501. Phase: Phase 3. Enrollment: 13 (actual). Results first posted October 1, 2026. Record: NCT05665088.
By the numbers
- Trials: 8, from 8 lead sponsors.
- Participants: 3,200 in all across 8 trials; median 350 per trial.
- Largest: Teva Pharmaceuticals USA's Estradiol trial, 1,050. Smallest: BioXcel Therapeutics' BXCL501 trial, 13.
- Phases as registered: 5 Phase 3, 3 Phase 2/Phase 3.
How this page is made
Code builds this page from the stream briefs linked above and from each trial's ClinicalTrials.gov record, read when the page was last built: sponsor, condition, intervention, phase and enrollment come from the record. No model writes this page. Registry results are summary data the sponsor posted; the record link opens them in full.